Moors & Cabot Inc. Lowers Holdings in Pfizer Inc. $PFE

Moors & Cabot Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 28.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 282,423 shares of the biopharmaceutical company’s stock after selling 112,305 shares during the quarter. Moors & Cabot Inc.’s holdings in Pfizer were worth $7,032,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Brighton Jones LLC lifted its position in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC lifted its position in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares in the last quarter. United Bank lifted its position in Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after acquiring an additional 6,415 shares in the last quarter. Sei Investments Co. raised its position in shares of Pfizer by 31.5% in the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after purchasing an additional 631,523 shares in the last quarter. Finally, HUB Investment Partners LLC raised its position in shares of Pfizer by 45.3% in the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after purchasing an additional 31,896 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PFE. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a report on Monday, March 2nd. Bank of America lowered their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Guggenheim boosted their price target on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer and Innovent Biologics announced a global licensing and collaboration deal to research and develop 12 early-stage cancer medicines, with potential value of up to $10.5 billion. The agreement expands Pfizer’s oncology pipeline and could create long-term revenue opportunities. Reuters article
• Positive Sentiment: The companies also described the partnership as a strategic global collaboration covering ADCs and multi-specific antibodies, which suggests Pfizer is strengthening its next-generation cancer portfolio. PR Newswire article
• Positive Sentiment: Recent coverage also highlighted steady early-stage pipeline progress, including a new Phase 1 trial update, reinforcing the view that Pfizer has several development programs moving forward. TipRanks article
• Neutral Sentiment: Bank of America recently lifted its price target on Pfizer to $27 from $26 after stronger quarterly results, indicating slightly improved sentiment but still a cautious overall stance. Yahoo Finance article

Pfizer Trading Down 0.2%

Shares of NYSE PFE opened at $26.16 on Friday. Pfizer Inc. has a 12 month low of $23.06 and a 12 month high of $28.75. The company has a market cap of $149.07 billion, a price-to-earnings ratio of 19.97 and a beta of 0.35. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The business has a fifty day simple moving average of $26.79 and a 200-day simple moving average of $26.28.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the prior year, the business earned $0.92 EPS. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. Pfizer’s dividend payout ratio is currently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.